VRPX — Virpax Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.42m
- -$0.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 3.18 | 4.2 | 12 | 21.8 | 15.7 |
Operating Profit | -3.18 | -4.2 | -12 | -21.8 | -15.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.31 | -4.34 | -12.1 | -21.7 | -15.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.31 | -4.34 | -12.1 | -21.7 | -15.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.31 | -4.34 | -12.1 | -21.7 | -15.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.31 | -4.34 | -12.1 | -21.7 | -15.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.69 | -8.78 | -18.1 | -18.5 | -13 |
Dividends per Share |